{
  "actions": [
    {
      "acted_at": "2007-11-14", 
      "committee": "Committee on Finance", 
      "references": [], 
      "status": "REFERRED", 
      "text": "Read twice and referred to the Committee on Finance.", 
      "type": "referral"
    }
  ], 
  "amendments": [], 
  "bill_id": "s2351-110", 
  "bill_type": "s", 
  "committees": [
    {
      "activity": [
        "referral", 
        "in committee"
      ], 
      "committee": "Senate Finance", 
      "committee_id": "SSFI"
    }
  ], 
  "congress": "110", 
  "cosponsors": [
    {
      "district": null, 
      "name": "Hatch, Orrin G.", 
      "sponsored_at": "2007-12-03", 
      "state": "UT", 
      "thomas_id": "01351", 
      "title": "Sen", 
      "withdrawn_at": null
    }
  ], 
  "enacted_as": null, 
  "history": {
    "awaiting_signature": false, 
    "enacted": false, 
    "vetoed": false
  }, 
  "introduced_at": "2007-11-14", 
  "number": "2351", 
  "official_title": "A bill to amend the Internal Revenue Code of 1986 to provide a tax credit for medical research related to developing qualified infectious disease products.", 
  "popular_title": null, 
  "related_bills": [
    {
      "bill_id": "hr4200-110", 
      "reason": "identical"
    }
  ], 
  "short_title": null, 
  "sponsor": {
    "district": null, 
    "name": "Schumer, Charles E.", 
    "state": "NY", 
    "thomas_id": "01036", 
    "title": "Sen", 
    "type": "person"
  }, 
  "status": "REFERRED", 
  "status_at": "2007-11-14", 
  "subjects": [
    "Antibiotics", 
    "Commerce", 
    "Communicable diseases", 
    "Drug industry", 
    "Health", 
    "Income tax", 
    "Medical tests", 
    "Pharmaceutical research", 
    "Preventive medicine", 
    "Research and development tax credit", 
    "Science, technology, communications", 
    "Taxation", 
    "Vaccines", 
    "Virus diseases"
  ], 
  "subjects_top_term": "Taxation", 
  "summary": {
    "as": "Introduced", 
    "date": "2007-11-14", 
    "text": "Amends the Internal Revenue Code to allow a general business tax credit for 50% of expenses paid for research and development of any qualified infectious disease product. Defines \"qualified infectious disease product\" as any antibiotic drug, antiviral, diagnostic test, biological product, or vaccine developed to treat, detect, prevent, or identify certain pathogens. Terminates such credit after 2012."
  }, 
  "titles": [
    {
      "as": "introduced", 
      "title": "A bill to amend the Internal Revenue Code of 1986 to provide a tax credit for medical research related to developing qualified infectious disease products.", 
      "type": "official"
    }
  ], 
  "updated_at": "2013-02-02T20:43:58-05:00"
}